Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $197.00 Average Price Target from Analysts

Krystal Biotech, Inc. (NASDAQ:KRYS) has been assigned an average rating of “Buy” from the nine analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $197.00.

Several research analysts have recently issued reports on KRYS shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. HC Wainwright restated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Tuesday, November 5th. Chardan Capital increased their target price on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a report on Monday, August 5th. Stifel Nicolaus boosted their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Finally, Citigroup increased their price objective on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th.

Insider Buying and Selling

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares in the company, valued at $296,814,424.32. This represents a 1.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 14.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jamison Private Wealth Management Inc. acquired a new position in shares of Krystal Biotech in the 2nd quarter valued at about $28,000. GAMMA Investing LLC raised its holdings in Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after buying an additional 93 shares during the period. Key Financial Inc purchased a new stake in Krystal Biotech during the second quarter worth approximately $28,000. Blue Trust Inc. increased its position in shares of Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after acquiring an additional 163 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new stake in shares of Krystal Biotech in the third quarter worth $53,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Stock Down 3.7 %

Shares of NASDAQ KRYS opened at $177.39 on Tuesday. The stock has a market capitalization of $5.10 billion, a price-to-earnings ratio of 104.08 and a beta of 0.82. Krystal Biotech has a 52 week low of $96.73 and a 52 week high of $219.34. The firm has a 50-day moving average price of $181.27 and a 200 day moving average price of $181.38.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The company’s quarterly revenue was up 879.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.67) EPS. Equities research analysts expect that Krystal Biotech will post 2.97 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).